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Dendritic polyglycerol anions for the selective
targeting of native and inflamed articular
cartilage†
Sabine Reimann,a Tobias Schneider,b Pia Welker,c Falko Neumann,a Kai Licha,a
Gundula Schulze-Tanzil,b Wolfgang Wagermaier,d Peter Fratzl*d and
Rainer Haag *a
The destruction of articular cartilage is a critical feature in joint diseases. An approach to selectively
target the damaged tissue is promising for the development of diagnostic and therapeutic agents. We
herein present the interaction of dendritic polyglycerol (dPG) anions with native and inflamed cartilage.
Confocal laser scanning microscopy revealed the inert character of dPG and low functionalized dPG
bisphosphonate (dPGBP7%) toward cartilage in vitro. An enhanced binding was observed for highly
functionalized dPG bisphosphonate, sulfate, and phosphate, which additionally showed a higher affinity
to IL-1b treated tissue. The mixed anion containing sulfate and bisphosphonate groups exhibited an
exceptionally high affinity to cartilage and strongly bound to collagen type II, as shown by a normalized
fluorescence-based binding assay. All polyglycerol anions, except dPGBP7%, were taken up by chondrocytes
within 24 h and no cytotoxicity was found up to 105 M. In a rheumatoid arthritis model, dPGBP7%
accumulated in mineralized compartments of inflamed joints and showed an increasing affinity to
cartilage with higher clinical scores, as evident from histological examinations. For dPGS no interaction
with bone but a strong binding to cartilage, independent of the score, was demonstrated. These results
make dPG anions promising candidates for the selective targeting of cartilage tissue.
Introduction
Inflammatory and degenerative joint diseases like rheumatoid
arthritis (RA) and osteoarthritis affect more than 200 million
people all over the world and therefore are some of the most
common global health issues.1 Besides alterations of the sub-
chondral bone, synovium, and synovial fluid, the course of
disease is characterized by the degradation of articular cartilage
including surface erosion, appearance of cracks, and chondro-
cyte apoptosis.2–5 Conventional therapies encompass the admin-
istration of non-steroidal anti-inflammatory drugs (NSAIDs) or
intra-articular injection of hyaluronic acid and corticosteroids.3,6,7
However, these treatments mainly focus on easing symptoms
to relief pain while cartilage destruction proceeds. The poor
efficacy of the common approaches to prevent tissue degenera-
tion is related to the lack of an efficient and selective drug
delivery to cartilage, currently limited by several factors: the low
permeability of the synovial membrane, the fast clearance of
drugs out of the joint cavity, the avascular structure of cartilage
that only permits compounds to enter the tissue by diffusion,
and the tight extracellular matrix (ECM) that acts as a barrier
for molecules to reach the site of action.8 With our ageing
population, the socio-economic impact of arthritis will increase
and novel approaches for the efficient and selective targeting of
cartilage are clearly needed.
Articular cartilage is a unique connective tissue, covering the
end of long bones, that shows a low potential of regeneration
due to its avascular, alymphatic, and non-innervated structure.3
The tissue mainly consists of glycoproteins, anionic proteoglycans
like aggrecan, and noncollagenous proteins that are embedded in
a dense network of collagen type II fibers and chondrocytes.9 The
latter sequester the hydrated ECM and regulate the formation
of the cartilage matrix.9 With a thin layer of fine collagen fibrils
parallel to the joint surface, the superficial zone is the upper-
most surface with a highly dense structure, which acts like a
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filter for molecules.10,11 The estimated average pore size of
cartilage is B6 nm, which lets small molecules penetrate the
cartilage tissue without hindrance, whereas larger particles are
prevented from diffusing into the ECM, which limits the efficacy
of anti-arthritic drugs.10,11 However, before entering, systemi-
cally administered agents must first reach the joint space by
leaving the blood vessels trough the synovial membrane, which
is restricted by its limited permeability showing a threshold of
B10 nm.12,13 Nevertheless, in arthritis as well as with increasing
age, a higher porosity of the ECM and the synovial membrane is
observed.12,14 Once in the synovial cavity, molecules are sub-
jected to a rapid clearance from the joint space resulting in poor
cartilage penetration.13 However, a screening of multiple drugs
and formulations for intra articular injections revealed a mole-
cular weight dependent retention time that showed small parti-
cles (o10 kDa) had a residence time of several hours, whereas
high molecular weight compounds persisted several weeks to
months in the synovial fluid.15 The destruction of the tissue
during arthritis is mediated by the interplay of inflammatory
cytokines, growth factors, and proteases which lead either
directly to the degradation of the ECM by cleaving collagen type II
and aggrecan or indirectly by altering cell signaling pathways.15
Particularly IL-1b leads to the induction of various degradative
matrix metalloproteinases, release of glycosaminoglycans from the
cartilage ECM and induction of inflammatorymediators.16 Although
disease-modifying anti-arthritic drugs show a high potential to
inhibit these factors and are assumed to have a high impact on
the treatment of rheumatoid and osteoarthritis, their application
is often very costly or related to numerous side-effects due to
immunosuppression if used for long-term therapy.3,17 A promising
approach to overcome the latter and additionally reduce clearance
from the affected tissue is the conjugation of drugs to polymeric
scaffolds that are able to efficiently and selectively bind to cartilage
and accumulate in the synovial joint.
In the past, various cationic agents were used as targeting
ligands for cartilage due to the high amount of anionic species
like chondroitin and keratan sulfate and hyaluronic acid within
the tissue.9 The binding affinity of quaternary amines to
the ECM based on electrostatic interactions with chondroitin
sulfate was already reported in 1975 and further demonstrated
for several pyridinium compounds in the following decades.18,19 In
ongoing studies radiolabeled quaternary amines were administered
in vivo for diagnostic applications and dipicolyamine was conjugated
to a fluorescent near infrared dye for the imaging of cartilage
degeneration.20–23 Recently, a cationic cartilage-specific NIR fluoro-
phore was developed as contrast agent and amine-functionalized
tantalum oxide particles have been applied for in vivo imaging
of articular cartilage by X-ray computed tomography, whereas
nitroxide-covered poly(propyleneimine) and poly(amido-amine)
(PAMAM) dendrimers were used as MRI contrast agents.24–26
Other approaches utilized the collagen type II specific peptide
sequence WYRGRL as a targeting ligand. The intra articular
injection of peptide-functionalized poly(propylene sulfide) nano-
particles showed a size dependent uptake into the cartilage
tissue.27 Whereas particles of 38 nm were able to penetrate
into the ECM and accumulated in chondrocytes, those with a
size of 96 nm did not enter and were found at the cartilage
surface. Moreover, Hu et al. combined collagen type II and
proteoglycan targeting properties with a therapeutic agent by
conjugation of the WYRGRL peptide and pepstatin A to a DOTAM
ligand bearing several amino groups to create a cartilage-targeted
drug carrier.28 Furthermore, also anionic systems based on lipid
nanoparticles covered with chondroitin sulfate have been developed
for the targeted delivery of diacerein and aceclofenac.29,30
However, these systems are still in an early stage of develop-
ment and suffer from poor efficacy as a result of a fast
clearance, lack of selectivity, insufficient enrichment in the
cartilage ECM, or, off-target side effects due to their accumula-
tion in the reticuloendothelial system (RES), which is related to
their physiochemical properties.
Polymeric structures can be prepared with various functional
groups in different sizes by which toxicity, renal excretion, and
recognition by the RES can be adjusted.31,32 Moreover, the
display of multiple ligands on the surface of a polymeric scaffold
allows for multivalent binding which leads to an increased
binding affinity along with an enhanced selectivity and is hence
a promising approach to improve the targeting properties of
a compound.33 Systems such as nanogels,34–36 self-assembled
supramolecular structures,37 and particles in the nanometer
range derived from biocompatible dendritic polyglycerol
(dPG)38 represent an ideal platform to target different tissues
due to their tunable physicochemical properties. For instance,
these architectures can be adjusted concerning their molecular
weight, size, stability, and morphology while surface charges can
be controlled simultaneously by the modification with anionic39
or cationic40 groups to obtain multivalent binding sites. In
previous studies, dPG-based agents were successfully applied
as targeted drug delivery systems,41–43 and the high affinity of
multivalent dendritic polyglycerol sulfate (dPGS) to inflamed
joints was revealed in a RA rat model44 which might have
been related to an enhanced accumulation in cartilage tissue.
Moreover, the selective targeting of collagenous compartments
within native and demineralized ovine bone was recently demon-
strated for sulfated and sulfonated dPG anions, whereas bisphos-
phonated, phosphated, and phosphonated compounds showed a
higher affinity to mineralized areas.45 The overall results indicate
a high binding potential of polyglycerol-based anions to cartilage
and represent promising candidates for the selective and efficient
targeting of the tissue in vitro and in vivo.
We herein present the targeting profiles of dye-labeled dPG
anions – in particular sulfates, bisphosphonates, phosphates,
and a mixed compound containing sulfate and bisphosphonate
groups – toward cartilage in vitro and in vivo as well as their
interaction with different ECM components. In vitro binding
properties toward cartilage were investigated by confocal laser
scanning microscopy (CLSM) with native and IL-1b treated
cartilage tissue, the latter to mimic the inflamed situation in
arthritis. The degradative effects of IL-1b on the cartilage ECM
are well known.46 In a collagen-induced arthritis (CIA) rat model,
ex vivo histological examinations of the joints and combined
investigations by CLSM and scanning electron microscopy
(SEM) revealed the targets of the polyanions on the tissue level.
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In order to identify molecular binding partners, the affinity of
prepared anions toward collagen was evaluated by applying
a fluorescence-based binding assay while the cellular uptake




Mesyl chloride (MsCl), sodium azide, triphenylphosphine (PPh3),
2-iminothiolane hydrochloride, sucrose, N-hydroxysuccinimide
(NHS), bovine serum albumin (BSA), methoxy carboxy poly-
ethylene glycol (mPEG-COOH), sodium ascorbate, Dulbecco’s
phosphate buffered saline (DPBS) buffer, DMF, pyridine, and
methanol were obtained from Sigma-Aldrich (Steinheim,
Germany). Chloroform was purchased from VWR (Radnor, PA,
USA), celite, sulfur trioxide pyridine complex (SO3 Py), and
Tween20 from Acros Organics (Geel, Belgium), THF from Roth
(Karlsruhe, Germany), N,N-diisopropylethylamine (DIPEA) from
Fluka (Buchs, Switzerland), copper sulfate pentahydrate, N-ethyl-
N0-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC), and
ethylendiamine-tetraacetic acid (EDTA) from Merck (Darmstadt,
Germany), deuterated solvents from Deutero (Kastellaun, Germany),
soluble bovine collagen type II from abcam (Cambridge, UK), and
ICC-labeled collagen II antibody from biorbyt (Cambridge, UK). All
chemicals were reagent grade and used without further purification.
Reactions sensitive to air or moisture were carried out under
argon atmosphere using flame-dried glassware and anhydrous
solvents. Ultrafiltration was performed in solvent-resistant
stirred cells obtained from Millipore (Billerica, Massachusetts,
USA) with PLAC-regenerated cellulose membranes (MWCO
1000 g mol1). Dialysis was performed in benzoylated cellulose
tubing purchased from Sigma-Aldrich (MWCO 2000 g mol1)
changing the solvent at least 5 times over a period of 48 h. SEC
was performed with Sephadext G-25 superfine (Sigma Aldrich,
Steinheim, Germany) in distilled water under room temperature
and pressure. 1H-, 13C-, and 31P-NMR spectra were recorded on a
Jeol ECX 400 spectrometer or on a Bruker Biospin Avance 700
spectrometer. Chemical shifts d were reported in ppm using
the deuterated solvent peak as the internal standard (CDCl3:
d (1H) = 7.26 ppm, d (13C) = 77.16 ppm; MeOD-d4: d (
1H) =
3.31 ppm, d (13C) = 49.00 ppm; D2O: d (
1H) = 4.79 ppm; acetone-D6:
d (1H) = 2.05 ppm, d (13C) = 29.84, 296.26 ppm; DMSO-D6: d (
1H) =
2.50 ppm, d (13C) = 39.52 ppm). The average polymer-to-dye ratio
was calculated by UV-Vis spectra from a 6 mM solution in DPBS at
pH 7.4 recorded on a LAMBDA 950 UV/Vis/NIR spectrometer
(PerkinElmer, Waltham, MA, USA) at 25 1C by applying a molar
extinction coefficient of 120000 M1 cm1 for ICC l (552 nm) and
of 100000 M1 cm1 for 6S-ICG (l = 785 nm). IR measurements
were recorded on a Nicolet Avatar 320 FT-IR equipped with a DTGS
detector from 4000 to 650 cm1 and evaluated with the software
EZ OMNIC ESP. Wavenumbers nmax were reported in cm
1; the
intensities of the absorption bands were assigned as strong (s),
medium (m), and weak (w). Combustion analysis was performed
on a VARIO EL III instrument (Elementar, Hanau, Germany)
using sulfanilic acid as the standard. DLS and z-potential
measurements were carried out on a Zetasizer Nano ZS
(Malvern Instruments Ltd, Worcestershire, U.K.) equipped with
a 4 mW He–Ne laser (l = 633 nm, NIBS) that operated with a
1731 scattering angle (backscatter). Hydrodynamic diameters were
determined in UV-transparent disposable cuvettes (UltraVette,
8.5 mm, Brand, Wertheim, Germany) at 25 1C. Samples were
dissolved in DPBS (DPBS, 1, without Ca2+, Mg2+, pH = 7.4,
Sigma-Aldrich, Steinheim, Germany) at a concentration of
2 mg mL1. The stated values are the mean of at least 15 inde-
pendent measurements. z-Potential measurements were con-
ducted at a concentration of 2 mg mL1 in phosphate buffer
(PB, 10 mM, pH 7.4) at 25 1C in folded DTS 1060 capillary cells
(Malvern Instruments Ltd, Worcestershire, U.K.). Data evaluation
was performed with Malvern Zetasizer Software 6.12. The stated
values and standard deviations are the mean of at least five
independent measurements with 15 scans each and are based
on the Smoluchowski model. ICP-MS measurements were con-
ducted on an Element 2 (Thermo Scientific, Waltham, MA, USA).
Cytotoxicity
Human articular cartilage was removed from femur heads or
tibia plateaus of patients receiving hip or knee replacements
in accordance with the institutional ethical committee of the
Charite´-Universita¨tsmedizin Berlin, Campus Benjamin Franklin
(EA4063/06). Chondrocytes were isolated by enzymatic digestion
of cartilage ECM and resuspended in chondrocyte growthmedium
as previously described.47 The metabolic activity of chondrocytes
was analyzed by an alamarBlues assay (Life technologies,
Darmstadt, Germany) using cells from three human donors
(mean age: 52.7 years, 2 male and 1 female donor) seeded in a
96-well plate at a density of 294.118 cells per mm2. 24 h after
seeding, cells were incubated with the respective unlabeled
polymer (Table S2, ESI†) or control compound at concentra-
tions of 103, 105, and 106 mol L1 for 24 h. 10% of
alamarBlues test reagent was added to the culture medium
(Biochrom, Berlin, Germany) and the read out was performed
by measuring the absorbance at a wavelength of 570 nm and a
reference wavelength of 595 nm every hour for 24 h using a
Genios microplate reader (Tecan Group, Ma¨nnedorf, Switzerland).
Glycerol served as positive non-toxic and sodium dodecyl sulfate
(SDS, Carl Roth, Karlsruhe, Germany) as toxic negative control at a
concentration of 103 mol L1 each. Stated cell activity refers to
100% of the reference (culture medium). Experiments were con-
ducted independently as triplicates with error bars representing
the standard deviation.
Uptake by articular chondrocytes
Human articular chondrocytes were seeded onto poly-L-lysine
coated glass cover slides (25 000 cells per well) placed in 6 well
plates. Cells were allowed to adhere for 24 h, incubated with
the respective ICC-labeled polymer (Table S1, ESI†) at a concen-
tration of 106 mol L1 for 24 h, and fixed for 15 min in
4% paraformaldehyde ready to use solution (PFA, Santa Cruz
Biotechnology, Heidelberg, Germany). The cytoskeleton was
stained using Phalloidin-Alexa488 (Santa Cruz Biotechnology,
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Heidelberg, Germany) and 40,6-diamidino-2-phenylindole dihydro-
chloride (DAPI, Sigma Aldrich, Munich, Germany) was used for
counter-staining of the cell nuclei. Images were taken with a DMi8
confocal microscope (Leica Microsystems, Wetzlar, Germany)
equipped with a 20 oil immersion microscope objective. Three
independent experiments with articular chondrocytes (femoral
head cartilage) from three human donors (mean age: 82.5 years,
2 female and 1 male donors) were performed.
Penetration depth into native and IL-1b treated cartilage
Vital cartilage was harvested from knee joints of 4–6 month old
pigs (derived from the slaughter house) and chips with a
diameter of 6 mm were prepared using a biopsy punch. The
probes were pre-incubated for 72 h (37 1C, 5% CO2) in cell
culture medium with or without 10 ng mL1 IL-1b, before
treatment with the respective ICC-labeled polymers (Table S1,
ESI†) for 24–72 h at a concentration of 106 mol L1, embedded
in TissueTek (Sakura Finetek, Staufen, Germany), and sliced
using a cryotome. Controls, which were treated with glycerol-ICC
were included in some experiments for detection of unspecific
background fluorescence (not shown). Cryosections were stained
with DAPI to visualize the cell nuclei. Images were taken with
the DMi8 confocal microscope (Leica Microsystems, Wetzlar,
Germany). In order to mimic inflamed tissue, cartilage chips
were treated with IL-1b (10 ng mL1) for 72 h prior to incubation
with the respective ICC conjugate.
Collagen type II binding affinity
Binding affinity studies were conducted on a 96-well plate (Nunc
FluoroNunc MaxiSorp, Thermo Scientific, Dreieich, Germany).
Each well was coated with dopamine containing hPG amine for
30 minutes as previously described.48 Soluble bovine collagen
type II (1 mgmL1 in 0.5 M acetic acid, pH 4.5) was immobilized
on the surface over night at 37 1C via a NHS/EDC coupling
procedure in DPBS buffer (1, pH 7.4).48 In order to block
remaining amine groups, the wells were incubated with a mixture
of mPEG-COOH (2 kDa, 0.1 mg mL1), NHS (0.01 mg mL1),
and EDC (0.1 mg mL1) in DPBS (1v/1v/1v) over night at 37 1C,
and washed with DPBS over 4 times. To prove the successful
immobilization of collagen type II on the surface, a collagen
type II antibody was used as a positive control. For that purpose,
a blocking solution (DPBS++ buffer, 2% BSA, 5% sucrose) was
added for 90 min at room temperature. Any residues were
removed by addition of a washing solution (DPBS++ buffer,
1% BSA, 0.05% Tween20) to the wells followed by PBS over 4 times
each. Subsequently, wells were incubated using an ICC-labeled
collagen type II antibody (1 mg mL1, 1 : 500 dilution in DPBS++
buffer and 0.1% BSA) for 1 h at room temperature followed by
washing with the washing solution and DPBS over 4 times each.
To investigate the binding affinity of the prepared polymers to
collagen type II, the respective ICC-conjugated polyanion was
added to the wells and incubated for 24 h at 37 1C at a concen-
tration of 105 mol L1 in DPBS directly after immobilization of
collagen type II and washed with DPBS buffer over 4 times. The
fluorescence intensity signal was measured by an Infinite 200 PRO
multimode microplate reader (Tecan, Ma¨nnedorf, Switzerland)
using an excitation wavelength of 525 nm and an emission
wavelength of 570 nm. Values were determined with an i-control
software from 16 reads per well from three independent
measurements.
Animal model
Lewis rats were purchased from Charles Rivers, fed a standard
diet and had access to drinking water ad libitum. Animal
studies were carried out in accordance with internationally
approved standards, have been validated and approved by
the State Office of Health and Social Affairs, Berlin (LAGeSo)
(no. G0427). Animals were killed in deep anesthesia by intra-
venous injection of T61 ad us. vet. (Intervet, Germany) at a dose
of 2 mL per animal after fluorescence imaging. RA was induced
in 15 female Lewis rats (150  10 g on arrival) by subcutaneous
injection of soluble bovine collagen type II (collagen induced
arthritis (CIA) model) as already published.49–51 Disease scoring
was performed 14 days post injection (p.i.) by evaluating the
clinical symptoms of the right and left ankle joints separately as
previously described.44 Comparable to other studies using the
same animal model, rats developed severe to mild RA with half
of the joints remaining unaffected by the disease.
Imaging device and image processing
The in vivo imaging was performed with a camera-based
fluorescence imaging system using an EMCCD Camera (iXon
BV887, Andor Technology, Belfast, UK). A light emitting diode
(LED) with lmax = 750 nm, a short pass filter (l = 750 nm, LCLL
750), and an illuminated area of 20 cm  20 cm was applied as
excitation source. Adjusted parameters were: exposure time
100 ms; EM gain 3000; shift time 0.9 ns per line; delay 18.8 ms;
preamplifier 4.6; detector temperature 65 1C; binning 2 pixels by
2 pixels; accumulation series with 100 frames, and accumulation
cycle time 200 ms. For suppression of excitation light, two fluores-
cence long pass filters (l50% = 800 nm, 5 OD, 800 LP, 800 ALP) were
applied and the images were analyzed as published by extracting
measured values in the regions of interest (ROI).51 Briefly, ROI were
set and illumination intensities were corrected for background.
Images are normalized to the mean intensity from a ROI placed
over the reference standard cube. Mean values are determined
in ROI for the right and left ankle.
In vivo and ex vivo imaging and fluorescence histology
For in vivo imaging, 6S-ICG conjugates were injected once in
sterile PBS at a dose of 2 mg kg1 intravenously (i.v.) via the tail
vein 14 days after inducing RA. Images were taken over 24 h after
administration of the dye conjugate. For histological recovery,
the rats additionally received the respective ICC-conjugate once
i.v. at a dose of 1 mg kg1. Fluorescence histology was performed
ex vivo on cryo sections (5 mm) of tibiotarsal articulations. For
this purpose, the entire feet were removed 3 h p.i., toes were cut
off, and cryo sections along the longitudinal-sagittal plane of the
respective joint were prepared, which were put on cellotape, and
fixed with acetone for 10 min. Remaining probes were stored
at 80 1C in TissueTek until further usage (see SEM and CLSM
imaging). Histology images were taken with a Leica DMRB
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fluorescence microscope (Leica Microsystems, Wetzlar, Germany)
equipped with a Spot digital camera and a Spot 32 v2.1 software
(Diagnostic Instruments, Sterling Heights, MI) using the 550 nm
channel for excitation. Cell nuclei were stained with DAPI.
Sample preparation and scanning electron microscopy (SEM)
For SEM imaging, feet from rats that additionally received the
respective ICC-conjugate once i.v. at a dose of 1 mg kg1 (see
ex vivo imaging) were used. For this purpose, TissueTek was
removed by hand from the respective foot and the TissueTek-
free joint sample was dehydrated over one week by immersion
in an ethanol series increasing the amount of ethanol from
50% to 100%. Each foot was embedded in a mixture of methyl
methacrylate (MMA), nonylphenyl-polyethyleneglycol acetate
and dibenzoyl peroxide, then heated in an oven (1 day at 40 1C,
1 day at 48 1C, 1 day at 55 1C), cut to length, ground, and polished
in an automatic polisher (Logitech PM5, Logitech Ltd, Glasgow,
UK). SEM images of the embedded joint samples were taken with
a FEI-Quanta 600FEG electron microscope (FEICompany, Oregon,
USA) at a working distance of 9.6 mm in low vacuum mode
(0.75 Torr). A large field detector (LFD) at 5 kV with a high field
width of 4.69 mm was used measuring the back-scattered-
electron signal from the sample surface. The joint of an untreated
rat was used for the adjustment of the fluorescence intensity,
which was applied for all other probes.
Confocal laser scanning microscopy (CLSM)
For CLSM imaging, feet from rats that additionally received the
respective ICC-conjugate once i.v. at a dose of 1 mg kg1 (see
ex vivo imaging) were used. CLSM micrographs were taken with
a Leica TCS SP8 (Leica Microsystems, Wetzlar, Germany)
equipped with a HCPL Fluotar 5/0.15 dry microscope objective.
The emission was measured at a range from 405 nm to 633 nm
and the excitation wavelength was set to 580 nm. Image stacks
were measured with a spatial pixel resolution of 1 mm  1 mm
until a penetration depth of 50 mm. All pictures were edited and
processed in ImageJ. All micrographs were taken using the same
laser- and microscope settings.
Results and discussion
Synthesis
In order to monitor their interaction with cartilage and different
ECM components, indocarbocyanine (ICC)-labeled dendritic
polyglycerol (dPG) anions, which varied in number of functional
groups and their anionic moiety, were synthesized. Consequently,
binding properties related to the anionic nature of the polymer
could be systematically studied to identify the most potential
agents to target healthy and malfunctioning cartilage tissue.
The polyanions derived from a neutral dPG scaffold (1) with
a molecular weight of Mn = 6000 g mol
1, a degree of branching
of 60%, and a poly dispersity index (PDI) of E1.6 which
was synthesized via a ring-opening multi-branching poly-
merization (ROMBP) as previously described.52 Dye conjugates
originated from the respective azide precursor by reduction
with triphenylphosphine (PPh3) and subsequent reaction
with the dye maleimide and 2-iminothiolane according to a
published procedure.38,50 ICC-labeled dPG (3) served as a
negative control for in vitro studies and derived from dPG azide
(2) with a degree of functionalization (dF) of 17% which was
synthesized by partial mesylation and azidation of the neutral
scaffold.40,45 Subsequent reduction of azide groups and dye
coupling gave dPG-ICC (3). The synthesis of ICC-labeled dPG
sulfate (dPGS-ICC 5) was accomplished by sulfation of 1 with
SO3 pyridine complex yielding dPGS azide (4) with a degree of
sulfation of 83%, subsequent reduction, and dye conjugation
(Fig. 1).45,53 For dPG bisphosphonate with a low dF (dPGBP7% 6)
a partial copper-catalyzed azide–alkyne click reaction was
applied on dPG azide (2) giving the compound with a dF of
7%.39,45 Reduction of remaining azide groups and subsequent
dye coupling yielded dPGBP7%-ICC (7) (Fig. 1). The mixed anion
containing sulfate and bisphosphonate groups (dPGS/BP7% 10)
was obtained by sulfation of half azide-functionalized dPG (8)
giving dPGS azide (9) with a degree of sulfation of 50% as
determined by elemental analysis, followed by partial click
reaction of the bisphosphonate alkyne (Fig. 2). A higher func-
tionalization with the bisphosphonate (BP) alkyne was either
not possible due to electrostatic shielding or led to precipita-
tion of the charged product. However, with a dPGS bearing a
lower amount of azide groups, the coupling of BP alkyne was
not observed, whereas the sulfation of dPGBP7% led to degrada-
tion of the anionic group as evident from absent signals
in the 31P-NMR. Subsequent azide reduction of 10 and dye
conjugation gave dPGS/BP7%-ICC (11). The synthesis of ICC-
functionalized dPG bisphosphonate (dPGBP-ICC 15) and phos-
phate (dPGP-ICC 16) was accomplished by click coupling of the
respective anionic alkyne on fully functionalized dPG azide (12)
giving dPGBP-N3 (13) or dPGP-N3 (14), followed by the reduction
of remaining azide groups and subsequent dye conjugation
(Fig. 2).39,45 The respective alkyne precursor was synthesized
according to a published procedure.39,45 In order to maintain
their native physicochemical properties and avoid an unspecific
interaction with cartilage due to conjugation with ICC, com-
pounds were functionalized with less than 0.2 dye per polymer in
average (Table S1, ESI†), as confirmed by UV-Vis spectroscopy in
PBS at 25 1C, in order to avoid entities with more than one dye at
a polymer molecule. However, for in vivo imaging, a near
infrared (NIR) dye was required in addition to a higher dye
loading per polymer to obtain an enhanced contrast. For this
purpose, a sulfonated indocyanine green derivative (6S-ICG) was
introduced into a dPGS (Fig. S2, ESI†) or dPGBP7% (Fig. S3, ESI†)
backbone by the common coupling procedure using 6S-ICG-
maleimide which gave the conjugate with a dye to polymer
ratio of 1.1 (dPGS-6S-ICG 5a) or 0.9 (dPGBP7%-6S-ICG 7a) after
purification. The presence of remaining free dye after purifica-
tion can be ruled out by applying size exclusion chromatography
(SEC) (Fig. S13, ESI†). For cytotoxicity studies, determination of
the zeta potential, and dynamic light scattering (DLS) measure-
ments, comparable unlabeled compounds were synthesized
(Table S2, ESI†). The prepared polyanions showedmolecular weights
between Mn = 8000 g mol
1 (dPGBP7% 7) and Mn = 30000 g mol
1
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(dPGBP 15) with a zeta potential of 13 to 27 mV in phosphate
buffer (PB) at pH 7.4 and a hydrodynamic diameter of 7–8 nm in
PBS which is in accordance to previously reported data.39
Penetration depth into native and inflamed articular cartilage
in vitro
The binding affinity to explanted native cartilage was already
described for dPGS, finding a maximum infiltration after
24 h.47 However, neither binding studies with other dPG anions
nor with inflamed cartilage in vitro have been conducted yet. In
order to evaluate the penetration depth of the anionic polymers
into native tissue in vitro, cartilage chips from porcine joints
were incubated for 24 h and 72 h with the respective ICC-labeled
polymer in culture medium at a concentration of 106 mol L1.
To mimic inflamed tissue as reported previously,16,46 samples
were pre-treated with IL-1b for 72 h before incubation with the
respective polyanion. Cartilage cryo slices were stained with
DAPI (blue) to visualize the cell nuclei. Binding and penetration
depth into the ECM were verified by applying CLSM (Fig. 3).
The compounds, which were not taken up serve as internal
control depicting no unspecific ICC-binding by the cartilage
ECM. Previous experiments (not shown), which included also
a glycerol-ICC-control, known not to be taken up by cells,
revealed no unspecific fluorescence. Neutral dPG (1) did not
show any interaction with native or IL-1b treated cartilage,
which confirmed the non-targeting properties and the inert
character of dendritic polyglycerol towards tissues and sur-
faces, which was already proven in various in vitro and in vivo
studies.45,54–56 In accordance with the previously described
uptake study, no internalization into chondrocytes and, more-
over, only a very weak binding to the ECM of native cartilage
were observed for dPGBP7% (7). In comparison, a slightly
stronger binding to the surface and an increased infiltration
into subjacent layers were found for dPGBP (15) and dPGP (16),
particularly after 72 h. Contrary to our expectations from
previous studies,47 also dPGS (5) showed a comparably low
binding affinity to the native porcine tissue. However, previous
in vitro experiments were conducted on human articular carti-
lage harvested during joint replacement surgeries in which
slight inflammation due to osteoarthritis or age-associated
degenerative changes cannot be ruled out, which could result
in the presence of molecular targets, absent in young porcine
tissue, and presumably led to variations in the binding
behavior of dPGS. This assumption is in agreement with the
observation that in response to a 72 h lasting dPGS treatment
combined with a 72 h pre-incubation with IL-1b, a substantial
ECM binding and internalization of dPGS could be observed
(Fig. 3). Surprisingly, dPGS/BP7% (11) showed an exceptionally
high binding affinity to the ECM, a high penetration depth, and
a high accumulation in the cell lacunas. In the absence of IL-1b,
Fig. 1 Idealized schematic structure of the dPG scaffold (1) (Mn = 6000 g mol
1) and the reaction pathway for the synthesis of ICC-labeled dPG (3),
dPGS (5), and dPGBP7% (7) from low functionalized dPG azide (2).
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for all polyanions a maximum enrichment in native cartilage
was determined after 24 h, which decreased over 72 h.
Although inflammatory processes were thought to increase
the penetration properties of the polyanions, IL-1b treatment
resulted in a minor binding of dPGS (5), dPGBP7% (7), and dPGBP
(15) within the first 24 h. Surprisingly, 72 h after incubation, a
much stronger affinity to the ECMwas determined for dPGBP and
dPGS with the latter greatly accumulating in deeper areas and cell
lacunas. In comparison, for dPGP (16) a strong penetration of the
tissue and uptake into articular chondrocytes was already
observed after 24 h. However, fluorescence signals within the
chondrocytes diminished after 72 h. dPGS/BP7% exhibited an even
higher affinity to the ECM of IL-1b treated tissue after 72 h as
compared to previous time points and native cartilage. These
results indicate that the penetration depth and binding affinity to
the ECM of cartilage is not only dependent on the number of
anionic moieties but also on the anionic group itself. Moreover,
a combination of different anionic functionalities could alter the
targeting properties of a polymer. However, the optimal ratio of
different moieties would have to be investigated systemically and
adjusted for the respective application.
Binding affinity to collagen type II
In recent studies with demineralized bovine bone, dye-labeled
dPG anions showed varyingly strong affinities to collagenous
compartments depending on the anionic group of the polymer.45
While the main collagen type within the organic matrix of bone
is collagen type I, the most abundant component of the ECM in
articular cartilage is collagen type II.57–59 Since dPG-based
polyanions showed a similar binding behavior to cartilage
and demineralized bone dependent on the anionic moiety,
collagen represents the most potential molecular binding
partner. However, no binding studies with dendritic polyanions
toward collagen have been conducted yet. In order to assess
quantitative affinities, a fluorescence read out was conducted
on a 96-well plate, with immobilized collagen type II, after
incubation with ICC-labeled polymers. To ensure a homogenous
distribution of the collagen on the surface, a dopamine-containing
hyperbranched polyglycerol (hPG) amine was conjugated to the well
prior to collagen immobilization.48 The remaining amine groups
were blocked with mPEG-COOH using an NHS/EDC coupling
procedure, and ICC-conjugated polymers (c = 105 mol L1 in
PBS) were incubated for 24 h at 37 1C. To prove the successful
coupling of the collagen, an ICC-labeled antibody specific to collagen
type II was used as a positive control (Fig. S15, ESI†). In order to
compare the binding properties among the polymers, fluores-
cence signals of the dPG anions were correlated with the dye
loading, corrected for the background signal, and are given as
percentage of collagen type II binding (Fig. 5). Unspecific binding
of the compounds to the non-functionalized well plate as well as
the blocked surface can be ruled out since no significant fluores-
cence signal in both cases was observed (Fig. S15, ESI†).
With a binding of less than 5% compared to the mixed
anion (11), neutral dPG (3) showed a very weak affinity to
collagen, as was already expected from the previous penetration
depth experiments with native cartilage. A remarkably low
affinity toward collagen was also found for dPGBP (15) which
bound with less than 10%. Surprisingly, dPGS (5) and dPGP (16)
showed similar results, although they were found to deeply
penetrate the ECM of cartilage, accumulating in chondrocyte
lacunas of subjacent layers in the inflamed state. In comparison
dPGBP7% (7) exhibited a slightly increased affinity to collagen of
Fig. 2 (a) Synthesis of dPGS/BP7%-ICC (11) via mesylation, azidation, and sulfation, followed by click reaction of alkyne-functionalized bisphosphonate,
reduction, and dye conjugation via maleimide coupling. (b) Reaction pathway for the preparation of dPGBP-ICC (15) and dPGP-ICC (16) via mesylation,
azidation, click reaction of the respective alkyne precursor, reduction, and dye conjugation via maleimide coupling.
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around 11% whereas dPGS/BP7% (11) provided far greater affi-
nity. Comparable binding patterns are also conceivable for other
collagen types, however, experiments to confirm this assumption
have not been conducted, as collagen type II is the most
abundant type in cartilage. In the previous studies investigating
the binding properties of glycosaminoglycans like chondroitin
sulfate and heparin to collagen, molecules with a higher charge
density showed a higher affinity due to electrostatic forces.60,61
Assuming that electrostatic interactions play a crucial role in
these binding events, the exceptionally high affinity to collagen
of the mixed anion was rather unexpected since dPGS in
comparison showed only minor binding properties, although it
provided more potential binding motifs and a comparable
charge density (Table S2, ESI†). Moreover, a zeta potential in
the same range (B20 mV) was also determined for dPGP and
dPGBP, while both compounds exhibited a low affinity to
collagen. Hence, the surface charge seems to play a minor role,
whereas the nature of the anionic moiety is more likely to be
important for binding and has to be taken into account, when it
comes to designing molecules for targeting collagen or cartilage.
However, these findings are in accordance with experiments
conducted on the penetration depth into native and inflamed
cartilage, which indicate that one of the binding partners of the
mixed anion is indeed collagen type II, whereas the molecular
targets of all other polyanions still remain unclear. Recent studies
with dPGS revealed a high protein absorption profile of the
polyanion, probably because of its interaction with basic amino
acid residues.62–64 Since the ECM of cartilage contains various
non-collagenous proteins, the binding of the polyanions to these
components has to be further investigated to identify their
molecular targets.57 Moreover, an interaction with proteogly-
cans, which may lead to an enhanced uptake into the cartilage
tissue, cannot be fully excluded. However, binding is consid-
ered unlikely due to electrostatic repulsion of the anions by
anionic residues of the proteoglycans.
Cellular uptake and cytotoxicity
Although dPG and dPGS have been intensively investigated
for their uptake properties by different cell types, only a few
studies have been conducted on other anionic polyglycerol
derivatives.45,47,65–68 In order to examine the uptake of the
prepared polyanions by human articular chondrocytes, cells
were incubated with ICC-labeled nanoparticles (Table S1, ESI,†
c = 106 mol L1) for 24 h (Fig. 4) and 72 h (not shown) at room
temperature. To demonstrate their subcellular location, cell
nuclei were stained with DAPI (blue) and actin cytoskeleton was
stained with phalloidin-Alexa488 (green). In compliance with
previous findings, no internalization of the neutral polymer (3)
Fig. 3 Penetration of ICC-labeled dPG anions (c = 106 mol L1) into native and IL-1b treated porcine cartilage 24 h and 72 h after incubation at 37 1C
and 5% CO2. The cell nuclei were stained with DAPI (blue). Arrows highlight the respective cartilage surface. In order to mimic inflamed cartilage, samples
were treated with IL-1b (10 ng mL1) for 72 h prior to incubation with the respective dye conjugate.
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was observed.45,65,68 Moreover, also dPGBP7% (7) did not show
any significant interaction, which indicates that a minimum
content of anionic moieties on the polymer is needed for cell
recognition. However, to test this assumption, the uptake of
nanoparticles, which vary in size, charge, and number of
anionic groups, would have to be investigated, since a size-
dependent internalization via an endocytotic pathway is also
possible, as already described for the neutral polymer.68 In
comparison, all other polyanions were incorporated by the cells
and were predominately found at the perinuclear region. The
strongest uptake was found for dPGP-ICC (16) assuming its
internalization into the nucleus due to the strong overlap of the
DAPI signal and the fluorescence of the dye-labeled anion.
Stainings of the actin-cytoskeleton at 24–72 h revealed no
changes due to toxic effects e.g. morphological alterations of
the cytoskeleton by the tested compounds. However, it must be
noted that no quantitative description can be deduced from
these results due to the different dye contents per polymer
(Table S1, ESI†). The influence of dendritic polyglycerol anions
on the metabolic activity of human chondrocytes was measured
by an alamarBlues assay after incubation of comparable non-
labeled polymers (Table S2, ESI†) at concentrations of 103,
105, and 106 mol L1. The relative metabolic activity
was determined 24 h after treatment by UV-Vis spectroscopy
measuring the amount of reduced alamarBlues by colorimetric
change. None of the synthesized compounds showed a signifi-
cant cytotoxicity in chondrocytes within the tested concen-
tration range, except for highly functionalized dPGBP (15) at a
concentration of 103 mol L1 (Fig. S14, ESI†). However, a
metabolic activity over 80% of the untreated or glycerol treated
controls was still found, which was rather unexpected, since
dPG anions showed a higher toxicity in murine fibroblasts.45
Surprisingly, in all other cases, a slightly increased metabolic
activity was observed after incubation with the respective
compound, which indicates a high cell compatibility with the
prepared probes. An insufficient cellular uptake of the com-
pounds leading to a low cytotoxic effect can be ruled out since
all polyelectrolytes except for dPG and dPGBP7% were inter-
nalized by chondrocytes. Moreover, an influence on the cell
metabolic activity of remaining copper used as catalyst during
the alkyne–azide click coupling can be excluded, because the
amount of copper ions was in the ppb range as determined
by inductively coupled plasma mass spectrometry (ICP-MS).
In conclusion, these results indicate a remarkable high chondrocyte
compatibility with the prepared polyanions. Even at 103 mol L1
concentration, the compounds did not show any severe cyto-
toxicity, although they underwent cellular uptake except for the
neutral polymer and dPGBP7%. However, non-toxic long-term
consequences remain to be proved in vivo for all compounds
tested here.
In vivo fluorescence imaging and fluorescence histology of
rat joints
The insufficient selectivity between different tissues and
undesired toxic side effects are one of the major drawbacks for
the efficient drug delivery to a certain target. With a hydrodynamic
diameter of 7–8 nm, the prepared dendritic polyanions were below
the threshold for renal clearance32 and were expected to be safely
and rapidly excreted from the body. In a previous study, highly
functionalized dPGBP was found to exhibit a remarkably high
affinity to mineralized compartments in bone by complexation of
calcium ions.45 However, applied in vivo, highly functionalized BP
polymers as well low-molecular weight compounds bear the risk of
severe side effects such as osteonecrosis or esophageal cancer.69
The utilization of bisphosphonated polymers with a low degree of
functionalization is a promising approach to overcome this issue,
and we assume that the selective targeting of bone in vivo can be
realized with dPGBP7% since this compound has a minor affinity
to cartilage in vitro. In contrast, dPGS was successfully applied as
Fig. 4 Uptake of ICC-labeled dPG derivatives at a concentration of
106 mol L1 by cultured human articular chondrocytes 24 h after incuba-
tion at 37 1C and 5% CO2. The cell nuclei were stained with DAPI (blue) and
the actin cytoskeleton was stained with phalloidin-Alexa488 (green). Fig. 5 Normalized collagen type II binding of ICC-labeled dPG anions to
collagen type II after incubation over 24 h at 37 1C (c = 106 mol L1) in PBS
pH 7.4 determined by a fluorescence read out. The binding was corrected
for the background signal and unspecific binding to the non-functionalized
surface. Normalization was performed due to different amounts of dyes
per polymer.
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dye conjugate for the imaging of inflamed joints in a CIA rat
model, which might also be related to an enhanced affinity toward
articular cartilage besides binding L-selectin and complement
factors.44,70 However, no experiments have been done yet to clarify
this assumption. Although dPGS/BP7% showed the highest affinity
to cartilage in vitro, bisphosphonate groups could influence the
binding properties to bone in vivo and could result in a decreased
selectivity. Hence, dPGS was used for the further studies, which
also showed a high affinity toward IL-1b treated cartilage.
In order to investigate their targeting properties of bone and
cartilage in vivo, 6S-ICG-conjugates of dPGS and dPGBP7% were
applied as imaging agents in healthy and CIA rats, the latter
induced by subcutaneous injection of soluble bovine collagen
type II. After 14 days 6S-ICG-conjugates were administered intra-
venously and near infrared (NIR) fluorescence imaging was
performed at 800 nm over 24 h. Fluorescence intensities were
quantified in vivo by normalization with a standard fluorescent
cube (Fig. 6). In healthy animals, undergoing no treatment with
bovine collagen type II, both compounds were found exclusively at
sites of injection, whereas an enrichment in inflamed joints was
observed in CIA rats depending on the clinical score (Fig. S16, ESI†).
For dPGS-6S-ICG, an accumulation was already demonstrated
after 10 min p.i. with a maximum enrichment after 1 h (data not
shown), which is comparable to previously reported studies.44
In contrast, dPGBP7%-6S-ICG (7a) slowly accumulated (Fig. S17,
ESI†) in the joints and had a maximum enrichment 24 h after
injection. However, fluorescence signals were comparably
weak and not only occurred in the inflamed articulations but
throughout the whole foot and the knee joints (Fig. 6).
For their histological recovery within CIA joints, rats addi-
tionally received the respective ICC-conjugate, and tibiotarsal
articulations were analyzed ex vivo 3 h p.i. by fluorescence
microscopy using the 550 nm channel for excitation. Whereas
dPGS-ICC (5) did not show any interaction with bone, a high
accumulation was observed in chondrocytes and cartilage
independent of the CIA score (Fig. 7), which demonstrates
the high sensitivity of dPGS for inflammatory and degenerative
processes at early stages of joint diseases. In comparison,
dPGBP7%-ICC (7) was exclusively found in the bone and around
the bonemarrow taken up by osteoblasts in joints with a score 0,
whereas no enrichment in the connective tissue or cartilage
occurred (Fig. S18, ESI†). So far, bisphosphonate compounds have
been described to mainly interact with bone-resorbing osteoclasts
either interfering in the mevalonic acid pathway or being incorpo-
rated as nonhydrolyzable adenosine triphosphate analogs leading
to apoptosis or cell inactivation.71–74 Nevertheless, BPs were also
reported to influence the cell proliferation of osteoblasts in vitro
and in vivo due to their cellular uptake which is in accordance with
the observed findings.75–78 The main affinity of bisphosphonates
to bone, however, is related to their strong complexation of
calcium cations which explains the accumulation of dPGBP7% in
the mineralized matrix compared to its absence in organic
compartments.79 In CIA joints with a score 2 and higher,
an enrichment of ICC-functionalized dPGBP7% (7) was also
observed in cartilage (Fig. 7), which was rather unexpected,
because the compound was only found in calcified areas in
joints with no clinical symptoms. There was, however, no uptake
by chondrocytes. The higher affinity to articular cartilage in
malfunctioning joints could be either related to a mineralization
Fig. 6 (A) Near infrared (NIR) images of rats with collagen induced rheumatoid arthritis @ 800 nm showing different scores, 24 h after intravenous
injection of dPGBP7%-6S-ICG (7a). (B) NIR-fluorescence intensity (NIR-FI) of rat joints with different clinical scores normalized at a standard cube at
different time points p.i. of dPGBP7%-6S-ICG (7a).
Fig. 7 Fluorescence microscopy images of tissue slides from tibiotarsal
articulations of rats with collagen-induced rheumatoid arthritis (CIA) 3 h
after intravenous injection of (A–C) ICC-labeled dPGBP7% (7) or (D) ICC-
labeled dPGS (5) (both red) with clinical scores of 0 (A) or 2 (B–D). The cell
nuclei were stained with DAPI (blue).
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of cartilage in RA or an enhanced destruction of the tissue which
would probably lead to more accessible binding partners and
has to be further investigated. Nevertheless, the data presented
here do not prove long-term biocompatibility.
SEM and CLSM
Histological examinations of tibiotarsal articulations from CIA
rats revealed the affinity of dPGS and dPGBP7% to cartilage in
inflamed joints to different extents. However, since the bis-
phosphonate only binds to mineralized compartments in healthy
tissue, it remains unclear whether the polyanion accumulates in
native or degraded cartilage or if calcified areas are addressed
which would indicate a mineralization of cartilage in RA. To clarify
this issue, scanning electron microscopy (SEM) images of the rat
joints embedded in PMMA were taken to distinguish between
highly and less mineralized areas and were superimposed with
CLSM pictures until the combined stacked areas fitted perfectly.
Superimposed images of dPGS (5) were used for comparison. To
minimize background signals due to autofluorescence of the
tissue, an untreated joint was used for the adjustment of the
fluorescence intensity (Fig. S20, ESI†).
In accordance with the histological examinations, the
bisphosphonated compound (7) was found to accumulate in
the bone of inflamed ankles as well as joints with no clinical
symptoms (Fig. 8). An enrichment of the polyanion was parti-
cularly found around the bone marrow, osteocyte lacunas, and
the epiphyseal plate, where metabolic processes proceed
and bone growth occurs,80 but also around blood vessels.
Surprisingly, the compound was not found in compartments
such as the epiphyseal line, the inner part of osteocyte lacunas,
and the calcified cartilage. Whereas only minor accumulation
in non-calcified cartilage was observed in joints with score 0,
a stronger enrichment was found in the cartilage of rats
with higher scores showing a high accumulation in specific
areas (Fig. 8). However, these areas did not show any sign of
calcification, which becomes obvious in the SEM pictures.
One possibility for the strong binding could be an advanced
destruction of the cartilage ECM during RA resulting in more
accessible binding partners. However, it remains unclear what
molecular targets the dPG bisphosphonate is binding to.
A general calcification of cartilage during the course of the
disease can be ruled out, since no changes in the grey values
and therefore in the mineral content of cartilage were found
(Fig. S19, ESI†). Nevertheless, a tendency towards higher
enrichment of dPGBP7% in cartilage with increasing CIA scores
was clearly observed (Fig. S21, ESI†).
In contrast, dPGS (5) shows a strong affinity to blood vessels
and cartilage independent of the CIA score (Fig. 8), although the
sulfated compound did not accumulate in joints of untreated rats.
These findings might be related to a high sensitivity of dPGS
towards molecular changes at very early stages of RA, where no
clinical symptoms are observed. In summary, dPG anions showed
differently pronounced affinities to bone, cartilage, and other
joint compartments, depending on the severity of the destruction,
which makes them interesting scaffolds for diagnostic and
therapeutic applications for arthritis at different stages. With its
high sensitivity toward cartilage destruction, dPGS and its deriva-
tives, for instance, could be used to selectively target degraded
cartilage at very early stages, whereas dPGBP7% could be applied
in more severe cases to identify cartilage lesions.
Conclusions
We herein demonstrated the synthesis of highly water-soluble, dye-
labeled dendritic polyglycerol anions, in particular sulfated,
phosphated, and bisphosphonated derivatives with a low and a
high degree of functionalization, as well as amixed anion containing
sulfate and bisphosphonate groups. By applying CLSM, differently
pronounced affinities of the polyanions toward articular cartilage
and its matrix components were verified and an enhanced binding
to the ECM was proven in the inflammatory state. This study
revealed that the interaction of polyanions with cartilage is highly
dependent on the anionic moiety, the number of anionic groups,
and the progression of tissue destruction. Moreover, it was shown
that the combination of different moieties on a polymer could alter
its targeting properties. These results make dendritic polyglycerol
anions promising candidates for therapeutic and diagnostic applica-
tions in inflammation-driven diseases, where selective targeting of
cartilage tissue is required. Taking into account that they also vary in
binding affinities toward calcified tissue as previously published by
our group, these anions can also be used for the differentiation
between bone and cartilage. Moreover, hybrid structures combining
different anionic moieties could be used to address compartments
Fig. 8 Superimposed images taken by confocal laser scanning micro-
scopy (CLSM) (red) and scanning electron microscopy (SEM) (grey) of CIA
rat joints embedded in PMMA showing different scores. Rats once received
ICC-labeled dPGBP7% (7) (A and B) or dPGS (5) (C and D) intravenously prior
to ex vivo imaging. Images show tibiotarsal articulations along the
longitudinal-sagittal plane. Feet were removed 3 h p.i. and stored at
80 1C in TissueTek until further usage.
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that show features of both tissues such as calcified cartilage.
However, further studies have to be conducted to identify the
molecular targets of the polyanions in order to understand
their interaction with the ECM.
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